metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population 9
mML - NA - PDL1 positive 1
mML - 1st line (L1)
mML - L1 - all population 7
mML - L1 - BRAF mutant 2
mML - L1 - BRAF wild 3
mML - 2nd line (L2)
mML - L2 - all population 11
mML - L2 - BRAF mutant 1
mesothelioma (MS)

All treatments
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone

versus all
vs non active control
vs placebo

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open